BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poynard T, Imbert-bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F; for the GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Journal of Viral Hepatitis 2002;9:128-33. [DOI: 10.1046/j.1365-2893.2002.00341.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 152] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Dufour DR. Assessment of liver fibrosis: Can serum become the sample of choice. Clin Chem. 2005;51:1763-1764. [PMID: 16189374 DOI: 10.1373/clinchem.2005.056929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222-230. [PMID: 12873819 DOI: 10.1016/s0168-8278(03)00171-5] [Cited by in Crossref: 233] [Cited by in F6Publishing: 80] [Article Influence: 12.9] [Reference Citation Analysis]
3 Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010;25:964-969. [PMID: 20546451 DOI: 10.1111/j.1440-1746.2009.06194.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
4 Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328-335. [PMID: 15590748 DOI: 10.1373/clinchem.2004.041764] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
5 Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan, TC, Reichman RC, Berggren R, Burning WJ, Brobst S. Correlation of Single Photon Emission Computed Tomography Parameters as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in the Setting of HIV and Hepatitis C Virus Coinfection: A Multicenter Trial of the Adult AIDS Clinical Trials Group: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;33:329-35. [DOI: 10.1097/00126334-200307010-00006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Fehr T, Riehle H, Nigg L, Grüter E, Ammann P, Renner EL, Ambühl PM. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. American Journal of Kidney Diseases 2003;42:193-201. [DOI: 10.1016/s0272-6386(03)00423-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
7 Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, de Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50. [DOI: 10.1053/j.gastro.2004.11.018] [Cited by in Crossref: 1666] [Cited by in F6Publishing: 1579] [Article Influence: 98.0] [Reference Citation Analysis]
8 Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, Moreau R, Poynard T, Lebrec D. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther. 2007;26:359-368. [PMID: 17635370 DOI: 10.1111/j.1365-2036.2007.03378.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
9 Mondal G, Saroha A, Bose PP, Chatterjee BP. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 2016;33:209-18. [PMID: 27034286 DOI: 10.1007/s10719-016-9658-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
10 Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;42:323-333. [PMID: 15080567 DOI: 10.1515/cclm.2004.058] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
11 Bedossa P, Paradis V. Approaches for treatment of liver fibrosis in chronic hepatitis C. Clin Liver Dis. 2003;7:195-210. [PMID: 12691467 DOI: 10.1016/s1089-3261(02)00076-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Khalaf N, White D, Kanwal F, Ramsey D, Mittal S, Tavakoli-Tabasi S, Kuzniarek J, El-Serag HB. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015;13:1521-1531.e3. [PMID: 25777972 DOI: 10.1016/j.cgh.2015.01.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
13 Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36:752-759. [PMID: 15571006 DOI: 10.1016/j.dld.2004.06.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
14 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
15 Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, Mchutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBRO Spect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 2009;16:178-86. [DOI: 10.1111/j.1365-2893.2008.01062.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
16 Anatol P, Robert F, Danuta P. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol 2005; 11(12): 1854-1858 [PMID: 15793880 DOI: 10.3748/wjg.v11.i12.1854] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
17 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
18 Tang IY, Walzer N, Aggarwal N, Tzvetanov I, Cotler S, Benedetti E. Management of the kidney transplant patient with chronic hepatitis C infection. Int J Nephrol. 2011;2011:245823. [PMID: 21603155 DOI: 10.4061/2011/245823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
19 Thabut D, Trabut J, Massard J, Rudler M, Muntenau M, Messous D, Poynard T. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006;26:271-8. [DOI: 10.1111/j.1478-3231.2005.01227.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
20 Wang J, Malik N, Yin M, Smyrk TC, Czaja AJ, Ehman RL, Venkatesh SK. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol 2017; 23(5): 859-868 [PMID: 28223730 DOI: 10.3748/wjg.v23.i5.859] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
21 Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549-1557. [PMID: 18846542 DOI: 10.1002/hep.22517] [Cited by in Crossref: 134] [Cited by in F6Publishing: 127] [Article Influence: 9.6] [Reference Citation Analysis]
22 Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389] [Cited by in Crossref: 362] [Cited by in F6Publishing: 330] [Article Influence: 21.3] [Reference Citation Analysis]
23 Berends MAM, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MGH, van de Kerkhof PCM, Drenth JPH. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007;27:639-45. [DOI: 10.1111/j.1478-3231.2007.01489.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
24 Kamar N, Rostaing L, Alric L. [Hepatitis C virus and renal transplantation]. Gastroenterol Clin Biol 2004;28:120-5. [PMID: 15060455 DOI: 10.1016/s0399-8320(04)94864-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Morra R, Munteanu M, Bedossa P, Dargere D, Janneau J, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-bismut F, Poynard T. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C: FIBROTEST AND PROTEOMIC PEAKS. Alimentary Pharmacology & Therapeutics 2007;26:847-58. [DOI: 10.1111/j.1365-2036.2007.03427.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
26 Duarte-rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Annals of Hepatology 2012;11:426-39. [DOI: 10.1016/s1665-2681(19)31456-5] [Cited by in Crossref: 31] [Article Influence: 3.1] [Reference Citation Analysis]
27 Amarapurkar D, Amarapurkar A. Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis. J Clin Exp Hepatol 2015;5:314-9. [PMID: 26900273 DOI: 10.1016/j.jceh.2015.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
28 Resino S, Bellón JM, Asensio C, Micheloud D, Miralles P, Vargas A, Catalán P, López JC, Alvarez E, Cosin J. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis. 2010;10:244. [PMID: 20723207 DOI: 10.1186/1471-2334-10-244] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
29 Vallet-pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [DOI: 10.1002/hep.21669] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 981] [Article Influence: 68.4] [Reference Citation Analysis]
30 Sporea I, Sirli R, Bota S, Popescu A, Sendroiu M, Jurchis A. Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. Ultrasound Med Biol. 2012;38:1310-1316. [PMID: 22698510 DOI: 10.1016/j.ultrasmedbio.2012.03.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
31 Morais CNLD, Carvalho BDM, Melo WGD, Melo FLD, Lopes EPDA, Domingues ALC, Jucá N, Martins JRM, Diniz GTN, Montenegro SML. Correlation of biological serum markers with the degree of hepatic fibrosis and necroinflammatory activity in hepatitis C and schistosomiasis patients. Mem Inst Oswaldo Cruz 2010;105:460-6. [DOI: 10.1590/s0074-02762010000400018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
32 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
33 Takyar V, Kleiner DE, Koh C. A Wolf in Sheep's Clothing in the Era of Non-Invasive Staging: Non-Hodgkin's Lymphoma Masquerading as Serologic HCV Cirrhosis. Am J Gastroenterol 2017;112:398-9. [PMID: 28154396 DOI: 10.1038/ajg.2016.550] [Reference Citation Analysis]
34 Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, Jang JW, Kim CW, Bae SH, Choi JY, Yoon SK. The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease. Korean J Hepatol 2009;15:59. [DOI: 10.3350/kjhep.2009.15.1.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
35 d'Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, Messous D, Morra R, Blot C, Poynard T. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J Viral Hepat 2006;13:182-9. [DOI: 10.1111/j.1365-2893.2005.00668.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
36 Crockett SD, Kaltenbach T, Keeffe EB. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time? Clinics in Liver Disease 2006;10:513-34. [DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
37 Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. Can J Gastroenterol Hepatol. 2015;29:139-144. [PMID: 25855877 DOI: 10.1155/2015/138530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
38 Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:183-97. [DOI: 10.1016/s1542-3565(04)00002-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
40 McHutchison J, Poynard T, Afdhal N. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol. 2006;4:1214-1220. [PMID: 16979947 DOI: 10.1016/j.cgh.2006.07.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
41 Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1970-1980. [PMID: 16128941 DOI: 10.1111/j.1572-0241.2005.41957.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
42 Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat. 2009;16:203-213. [PMID: 19175871 DOI: 10.1111/j.1365-2893.2008.01065.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
43 White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768. [PMID: 21858849 DOI: 10.1002/hep.24618] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
44 Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q, Guo X. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2020;10:13519. [PMID: 32782270 DOI: 10.1038/s41598-020-70241-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670-1681. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 20.6] [Reference Citation Analysis]
46 Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48:146-153. [PMID: 12645802 DOI: 10.1023/a:1021702902681] [Cited by in Crossref: 56] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
47 Liu Y, El-Serag HB, Jiao L, Lee J, Moore D, Franco LM, Tavakoli-Tabasi S, Tsavachidis S, Kuzniarek J, Ramsey DJ. WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One. 2013;8:e84407. [PMID: 24386373 DOI: 10.1371/journal.pone.0084407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
48 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
49 Trocme C, Leroy V, Sturm N, Hilleret MN, Bottari S, Morel F, Zarski JP. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006;13:643-51. [PMID: 16970595 DOI: 10.1111/j.1365-2893.2006.00730.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
50 Köpke-Aguiar LA, Martins JR, Passerotti CC, Toledo CF, Nader HB, Borges DR. Serum hyaluronic acid as a comprehensive marker to assess severity of liver disease in schistosomiasis. Acta Trop. 2002;84:117-126. [PMID: 12429428 DOI: 10.1016/s0001-706x(02)00136-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
51 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
52 Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2008;32:858-65. [DOI: 10.1016/j.gcb.2008.05.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
53 Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, Thursz M; HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-9. [PMID: 12631672 DOI: 10.1136/gut.52.4.574] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
54 Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721-725. [PMID: 12646795 DOI: 10.1097/00002030-200303280-00010] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 7.8] [Reference Citation Analysis]
55 Sporea I, Bota S, Gradinaru-taşcău O, Şirli R, Popescu A, Jurchiş A. Which are the cut-off values of 2D-Shear Wave Elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering Transient Elastography (TE) as the reference method? European Journal of Radiology 2014;83:e118-22. [DOI: 10.1016/j.ejrad.2013.12.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
56 Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T;  LIDO Study Group;  CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [PMID: 16503961 DOI: 10.1186/1471-230x-6-6] [Cited by in Crossref: 290] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
57 Rubio A, Monpoux F, Huguon E, Truchi R, Triolo V, Rosenthal-Allieri MA, Deville A, Rosenthal E, Boutté P, Tran A. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr. 2009;49:599-606. [PMID: 19668009 DOI: 10.1097/mpg.0b013e3181a15b72] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
58 Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83:127-134. [PMID: 19443053 DOI: 10.1016/j.antiviral.2009.04.002] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 7.4] [Reference Citation Analysis]
59 White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. J Clin Gastroenterol 2012;46:779-88. [PMID: 22955261 DOI: 10.1097/MCG.0b013e318266f6eb] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Selimoglu MA, Yagcl RV, Yüce G. Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B. World J Gastroenterol 2004; 10(19): 2864-2866 [PMID: 15334687 DOI: 10.3748/wjg.v10.i19.2864] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz’ko V. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:204-213. [PMID: 21354889 DOI: 10.1016/j.clinre.2011.01.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
62 Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160-1174. [PMID: 15180741 DOI: 10.1111/j.1572-0241.2004.30110.x] [Cited by in Crossref: 400] [Cited by in F6Publishing: 374] [Article Influence: 22.2] [Reference Citation Analysis]
63 Camacho VR, Silveira TR, Oliveira JR, Barros SG, Cerski CT. Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors. Arq Gastroenterol 2007;44:118-22. [PMID: 17962855 DOI: 10.1590/s0004-28032007000200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
64 Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Thiollière JM, Piette JC, Imbert-Bismut F, Halfon P, Poynard T, Cacoub P. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. Clin Biochem 2006;39:715-21. [PMID: 16765932 DOI: 10.1016/j.clinbiochem.2006.04.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
65 Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32:22-39. [PMID: 18973844 DOI: 10.1016/s0399-8320(08)73991-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
66 Poynard T. Les interférons ont-ils une action antifibrosante ?Le point de vue de l'hépatologue. La Revue de Médecine Interne 2002;23:517S-21S. [DOI: 10.1016/s0248-8663(02)00668-9] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
67 Poynard T, Imbert-bismut F, Munteanu M, Messous D, Thabut D, Ratziu V, Benhamou Y. Biomarkers as non-invasive assessment of hepatic fibrosis in chronic hepatitis C. J Gastroenterol Hepatol 2004;19:S236-45. [DOI: 10.1111/j.1440-1746.2004.03680.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Attia D, Pischke S, Negm AA, Rifai K, Manns MP, Gebel MJ, Lankisch TO, Potthoff A. Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. Dig Liver Dis. 2014;46:625-631. [PMID: 24666759 DOI: 10.1016/j.dld.2014.02.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
69 Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260-1267. [PMID: 16771947 DOI: 10.1111/j.1572-0241.2006.00556.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.2] [Reference Citation Analysis]
70 Li Y, Cai Q, Zhang Y, Xie Q, Xu N, Jiang X, Li J, Li X, Zhang Z. Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: Significant reduction in liver biopsy. Hepatol Res. 2016;46:1367-1379. [PMID: 26970087 DOI: 10.1111/hepr.12696] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
71 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 131.1] [Reference Citation Analysis]
72 Miailhes P, Pradat P, Chevallier M, Lacombe K, Bailly F, Cotte L, Trabaud MA, Boibieux A, Bottero J, Trepo C. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat. 2011;18:61-69. [PMID: 20196798 DOI: 10.1111/j.1365-2893.2010.01275.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
73 Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Moussalli J, Ratziu V, Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One 2008;3:e2573. [PMID: 18596917 DOI: 10.1371/journal.pone.0002573] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
74 Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40. [PMID: 17937811 DOI: 10.1186/1471-230x-7-40] [Cited by in Crossref: 205] [Cited by in F6Publishing: 75] [Article Influence: 13.7] [Reference Citation Analysis]
75 Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci. 2016;61:3118-3139. [PMID: 27435327 DOI: 10.1007/s10620-016-4254-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
76 Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol 2008; 14(21): 3396-3402 [PMID: 18528937 DOI: 10.3748/wjg.14.3396] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
77 Atta M, Cabral M, Santos G, Paraná R, Atta A. Inflammation biomarkers in chronic hepatitis C: association with liver histopathology, HCV genotype and cryoglobulinemia. Inflamm Res. 2012;61:1101-1106. [PMID: 22718074 DOI: 10.1007/s00011-012-0502-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
78 Rodart IF, Pares MM, Mendes A, Accardo CM, Martins JRM, Silva CB, Carvalho FO, Barreto JA, Reis MG, Tersariol ILS, Nader HB. Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors. Molecules 2021;26:3892. [PMID: 34202190 DOI: 10.3390/molecules26133892] [Reference Citation Analysis]
79 Hashem AM, Rasmy MEM, Wahba KM, Shaker OG. Single stage and multistage classification models for the prediction of liver fibrosis degree in patients with chronic hepatitis C infection. Computer Methods and Programs in Biomedicine 2012;105:194-209. [DOI: 10.1016/j.cmpb.2011.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
80 Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97:2419-2425. [PMID: 12358267 DOI: 10.1111/j.1572-0241.2002.05997.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 2.8] [Reference Citation Analysis]
81 Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011-1019. [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030] [Cited by in Crossref: 177] [Cited by in F6Publishing: 163] [Article Influence: 14.8] [Reference Citation Analysis]
82 Pockros PJ. Noninvasive Markers of Fibrosis in Chronic Hepatitis Patients: . Journal of Clinical Gastroenterology 2006;40:461-3. [DOI: 10.1097/00004836-200607000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol. 2010;45:349-356. [PMID: 20017652 DOI: 10.3109/00365520903490606] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
84 Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52:1887-1896. [PMID: 16931569 DOI: 10.1373/clinchem.2006.070961] [Cited by in Crossref: 170] [Cited by in F6Publishing: 167] [Article Influence: 10.6] [Reference Citation Analysis]
85 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
86 Soriano V, Martín-carbonero L, García-samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003;17:751-3. [DOI: 10.1097/00002030-200303280-00015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
87 Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8. [PMID: 15387887 DOI: 10.1186/1476-5926-3-8] [Cited by in Crossref: 239] [Cited by in F6Publishing: 247] [Article Influence: 13.3] [Reference Citation Analysis]
88 Ginde S, Hohenwalter MD, Foley WD, Sowinski J, Bartz PJ, Venkatapuram S, Weinberg C, Tweddell JS, Earing MG. Noninvasive Assessment of Liver Fibrosis in Adult Patients Following the Fontan Procedure: Liver Fibrosis in Adult Fontan Patients. Congenital Heart Disease 2012;7:235-42. [DOI: 10.1111/j.1747-0803.2012.00632.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
89 Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol. 2010;34:16-22. [PMID: 19726147 DOI: 10.1016/j.gcb.2009.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
90 Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138-148. [PMID: 21083589 DOI: 10.1111/j.1365-2036.2010.04500.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
91 Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38:481-492. [PMID: 12883493 DOI: 10.1053/jhep.2003.50319] [Cited by in Crossref: 181] [Cited by in F6Publishing: 168] [Article Influence: 9.5] [Reference Citation Analysis]
92 Halfon P, Bourlière M, Pénaranda G, Cacoub P. [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. Rev Med Interne 2006;27:751-61. [PMID: 16815598 DOI: 10.1016/j.revmed.2006.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
93 Rosenthal-allieri MA, Tran A, Halfon P, Imbert-bismut F, Munteanu M, Messous D, Peritore M, Poynard T, Bernard A. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2007;31:815-21. [DOI: 10.1016/s0399-8320(07)73971-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
94 Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh RC, Cotton D. Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. American Journal of Gastroenterology 2010;105:1346-53. [DOI: 10.1038/ajg.2009.746] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 9.3] [Reference Citation Analysis]
95 Cadranel JF, Mathurin P. Prothrombin index decrease: a useful and reliable marker of extensive fibrosis. Eur J Gastroenterol Hepatol. 2002;14:1057-1059. [PMID: 12362094 DOI: 10.1097/00042737-200210000-00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
96 Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-rust M, Sarrazin C, Zeuzem S, Welker M. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016;23:994-1002. [DOI: 10.1111/jvh.12578] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 15.3] [Reference Citation Analysis]
97 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
98 Cabrera Álvarez G, Madrid-marina V, Jimenez-mendez R, Leon Buitimea A, Bahena Román M, Cortez-gomez R, Reyes Esparza J, Rodríguez-fragoso L. Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis. Annals of Hepatology 2007;6:233-41. [DOI: 10.1016/s1665-2681(19)31904-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
99 Narasimhan G, Sargios TN, Kalakuntla R, Homel P, Clain DJ, Theise ND, Bodenheimer HC, Min AD. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat 2006;13:783-6. [DOI: 10.1111/j.1365-2893.2006.00763.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
100 Nahon P, Thabut G, Ziol M, Htar MT, Cesaro F, Barget N, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Beaugrand M. Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2006;101:2744-2751. [PMID: 17227522 DOI: 10.1111/j.1572-0241.2006.00816.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
101 Li X, Wang X, Gao P. Diabetes Mellitus and Risk of Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:5202684. [PMID: 29379799 DOI: 10.1155/2017/5202684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
102 Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, Wang CC. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010;17:58. [PMID: 20630109 DOI: 10.1186/1423-0127-17-58] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
103 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 219] [Article Influence: 15.5] [Reference Citation Analysis]
104 Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, Vallet-Pichard A, Fontaine H, Pol S. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2009;29:409-415. [PMID: 19035983 DOI: 10.1111/j.1365-2036.2008.03895.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
105 Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450-454. [PMID: 12600957 DOI: 10.1373/49.3.450] [Cited by in Crossref: 166] [Cited by in F6Publishing: 159] [Article Influence: 8.7] [Reference Citation Analysis]
106 Shukla A, Kapileswar S, Gogtay N, Joshi A, Dhore P, Shah C, Abraham P, Bhatia S. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2015;34:281-5. [DOI: 10.1007/s12664-015-0580-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
107 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314-318. [PMID: 14748879 DOI: 10.1111/j.1440-1746.2003.03256.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
109 Mooney P, Hayes P, Smith K. The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006;20:1351-8. [PMID: 17004233 DOI: 10.1002/bmc.704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
110 Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, Mohammadkani A, Derakhshan MH, Zamani F, Samiee S, Malekzadeh R. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005;5:32. [PMID: 16221307 DOI: 10.1186/1471-230X-5-32] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
111 Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. European Journal of Gastroenterology & Hepatology 2019;31:67-74. [DOI: 10.1097/meg.0000000000001259] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
112 Czaja AJ. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385-406. [PMID: 24387318 DOI: 10.1111/apt.12592] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
113 Pourhassan A, Fouladi DF, Samani SM, Asl SM. Serum Zinc and Haptoglobin in Noncirrhotic Azeri Patients with Chronic Active Hepatitis C: a Case-Control Study. Biol Trace Elem Res 2015;167:187-93. [PMID: 25795173 DOI: 10.1007/s12011-015-0309-4] [Reference Citation Analysis]
114 Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography vs transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138-1147. [PMID: 23859217 DOI: 10.1111/liv.12240] [Cited by in Crossref: 279] [Cited by in F6Publishing: 255] [Article Influence: 31.0] [Reference Citation Analysis]
115 Bota S, Sporea I, Sirli R, Popescu A, Jurchis A. Factors which influence the accuracy of acoustic radiation force impulse (ARFI) elastography for the diagnosis of liver fibrosis in patients with chronic hepatitis C. Ultrasound Med Biol. 2013;39:407-412. [PMID: 23245820 DOI: 10.1016/j.ultrasmedbio.2012.09.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
116 Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology. 2005;42:838-845. [PMID: 16121354 DOI: 10.1002/hep.20814] [Cited by in Crossref: 145] [Cited by in F6Publishing: 149] [Article Influence: 8.5] [Reference Citation Analysis]
117 Sporea I, Şirli R, Popescu A, Bota S, Badea R, Lupşor M, Focşa M, Dănilă M. Is it better to use two elastographic methods for liver fibrosis assessment? World J Gastroenterol 2011; 17(33): 3824-3829 [PMID: 21987625 DOI: 10.3748/wjg.v17.i33.3824] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
118 Gonzalez HC, Duarte-Rojo A. Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes. Curr Gastroenterol Rep 2016;18:32. [PMID: 27177638 DOI: 10.1007/s11894-016-0508-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
119 Kim BK, Kim SA, Park YN, Cheong JY, Kim HS, Park JY, Cho SW, Han KH, Chon CY, Moon YM. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int. 2007;27:969-976. [PMID: 17696936 DOI: 10.1111/j.1478-3231.2007.01519.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
120 Viana MSVB, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Annals of Hepatology 2009;8:26-31. [DOI: 10.1016/s1665-2681(19)31807-1] [Cited by in Crossref: 35] [Article Influence: 2.7] [Reference Citation Analysis]
121 Hu XR, Cui XN, Hu QT, Chen J. Correlation between serum fibrosis markers and the degree of liver fibrosis in patients with chronic hepatitis. Shijie Huaren Xiaohua Zazhi 2010; 18(14): 1501-1503 [DOI: 10.11569/wcjd.v18.i14.1501] [Reference Citation Analysis]
122 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
123 Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867-872. [PMID: 16109665 DOI: 10.1080/00365520510015674] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
124 Popescu A, Bota S, Sporea I, Sirli R, Danila M, Racean S, Suseanu D, Gradinaru O, Ivascu Siegfried C. The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results. Ultrasound Med Biol. 2013;39:579-584. [PMID: 23415282 DOI: 10.1016/j.ultrasmedbio.2012.11.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
125 Petta S, Macaluso FS, Barcellona MR, Cammà C, Cabibi D, Di Marco V, Craxì A. Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One. 2012;7:e51165. [PMID: 23227248 DOI: 10.1371/journal.pone.0051165] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
126 Bota S, Sporea I, Sirli R, Popescu A, Danila M, Costachescu D. Intra- and Interoperator Reproducibility of Acoustic Radiation Force Impulse (ARFI) Elastography–Preliminary Results. Ultrasound in Medicine & Biology 2012;38:1103-8. [DOI: 10.1016/j.ultrasmedbio.2012.02.032] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
127 Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-otero R, Carrilho F, Schmidt W, Berg T, Mcgarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of Hepatology 2011;54:227-35. [DOI: 10.1016/j.jhep.2010.06.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
128 Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-542. [PMID: 16825937 DOI: 10.1097/00004836-200607000-00013] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
129 Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306. [DOI: 10.1002/hep.21520] [Cited by in Crossref: 168] [Cited by in F6Publishing: 159] [Article Influence: 11.2] [Reference Citation Analysis]
130 Bota S, Paternostro R, Etschmaier A, Schwarzer R, Salzl P, Mandorfer M, Kienbacher C, Ferlitsch M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. Ultrasound Med Biol. 2015;41:2340-2349. [PMID: 26004669 DOI: 10.1016/j.ultrasmedbio.2015.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
131 Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429-434. [PMID: 15152612 DOI: 10.1038/nm1006] [Cited by in Crossref: 321] [Cited by in F6Publishing: 299] [Article Influence: 17.8] [Reference Citation Analysis]
132 Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol. 2007;41:103-110. [PMID: 17198072 DOI: 10.1097/01.mcg.0000225612.86846.82] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
133 Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S. Diagnostic Accuracy of the Fibrotest in Hemodialysis and Renal Transplant Patients with Chronic Hepatitis C Virus: . Transplantation 2005;80:1550-5. [DOI: 10.1097/01.tp.0000183399.85804.02] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
134 Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret M, Morel F, Zarski J. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid. Am J Gastroenterol 2004;99:271-9. [DOI: 10.1111/j.1572-0241.2004.04055.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 9.3] [Reference Citation Analysis]
135 Poynard T, Munteanu M, Ngo Y, Ratziu V. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C. Aliment Pharmacol Ther 2009;30:1183-5; author reply 1185-6. [PMID: 19888919 DOI: 10.1111/j.1365-2036.2009.04115.x] [Reference Citation Analysis]
136 Poynard T. [The Fibrotest is an ethical choice because it is a cost-effective and anti-inflationistic test. Response to Jean Louis Payen and Jean Marie Combis]. Gastroenterol Clin Biol 2004;28:929-31. [PMID: 15523238 DOI: 10.1016/s0399-8320(04)95166-4] [Reference Citation Analysis]
137 Halfon P, Bourlière M, Pénaranda G, Cacoub P. Intérêt et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l'hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007;36:457-66. [DOI: 10.1016/j.lpm.2007.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
138 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s9051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
139 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
140 Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3:167-174. [PMID: 15704051 DOI: 10.1016/s1542-3565(04)00625-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
141 Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med 2017;15:204. [PMID: 29151365 DOI: 10.1186/s12916-017-0969-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
142 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
143 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
144 Selph SS, Ginsburg AD, Chou R. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev 2014;3:107. [PMID: 25239493 DOI: 10.1186/2046-4053-3-107] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
145 de Lédinghen V, Poynard T, Wartelle C, Rosenthal E. [Non-invasive evaluation of liver fibrosis in hepatitis C]. Gastroenterol Clin Biol 2008;32:S90-5. [PMID: 18675186 DOI: 10.1016/S0399-8320(08)73271-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
146 Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616-623. [PMID: 15743360 DOI: 10.1111/j.1572-0241.2005.41289.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 8.2] [Reference Citation Analysis]
147 Poynard T, Imbert-bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis? Expert Review of Molecular Diagnostics 2014;5:15-21. [DOI: 10.1586/14737159.5.1.15] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
148 Poynard T, Munteanu M, Imbert-bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V. Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clinical Chemistry 2004;50:1344-55. [DOI: 10.1373/clinchem.2004.032227] [Cited by in Crossref: 216] [Cited by in F6Publishing: 213] [Article Influence: 12.0] [Reference Citation Analysis]
149 Oguz A, Atay AE, Tas A, Seven G, Koruk M. Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. Gut Liver 2013;7:82-8. [PMID: 23424009 DOI: 10.5009/gnl.2013.7.1.82] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
150 Tyson GL, Richardson PA, White DL, Kuzniarek J, Ramsey DJ, Tavakoli-Tabasi S, El-Serag HB. Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. J Clin Gastroenterol 2013;47:545-52. [PMID: 23426443 DOI: 10.1097/MCG.0b013e31827244d9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-bismut F, Poynard T. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology;37:1220-1. [DOI: 10.1053/jhep.2003.50109] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 3.8] [Reference Citation Analysis]